Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

Blood

Volumn 126, Issue 14, 2015, Pages 1699-1706

  Wang, Wei ^a   Cortes, Jorge E ^a   Lin, Pei ^a   Beaty, Michael W ^b   Ai, Di ^a   Amin, Hesham M ^a   McDonnell, Timothy J ^a   Ok, Chi Young ^a   Kantarjian, Hagop M ^a   Medeiros, L Jeffrey ^a   Hu, Shimin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLAST TRANSFORMATION; CANCER PATIENT; CANCER PROGNOSIS; CHROMOSOME 3Q; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 3; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CYTOGENETICS; FEMALE; GENE LOCUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; CHROMOSOME 3; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MORTALITY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; YOUNG ADULT;

EID: 84947933015     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-05-646489     Document Type: Article

References (40)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824-830.
2. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405): 290-293.
3. Fabarius A, Leitner A, Hochhaus A, et al; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118(26): 6760-6768.
4. Hehlmann R. How I treat CML blast crisis. Blood. 2012;120(4):737-747.
5. Haferlach C, Bacher U, Schnittger S, Weiss T, Kern W, Haferlach T. Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment. Leukemia. 2010;24(3):638-640.
6. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7): 2254-2264.
7. Neviani P. Genetic events other than BCR-ABL1. Curr Hematol Malig Rep. 2014;9(1):24-32.
8. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107(2): 76-94.
9. Fioretos T, Johansson B. Chronic myeloid leukemia. In: Heim S, Mitelman F, eds. Cancer Cytogenetics. Hoboken, NJ: Wiley-Blackwell; 2009:179-207.
10. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
11. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101(10): 3794-3800.
12. Cortes J, Talpaz M, O'Brien S, et al. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol. 1998;16(10):3279-3285.
13. Verma D, Kantarjian H, Shan J, et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010;116(11): 2673-2681.
14. O'Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002;100(5):1628-1633.
15. Luatti S, Castagnetti F, Marzocchi G, et al; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML. Additional chromosomal abnormalities in Philadelphiapositive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood. 2012;120(4): 761-767.
16. Lugthart S, Gröschel S, Beverloo HB, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010;28(24):3890-3898.
17. Grimwade D, Hills RK, Moorman AV, et al; National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
18. Haferlach C, Bacher U, Haferlach T, et al. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML. Leukemia. 2011;25(5): 874-877.
19. Rogers HJ, Vardiman JW, Anastasi J, et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3) (q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014;99(5):821-829.
20. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.
21. Rubin CM, Larson RA, Anastasi J, et al. t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 1990;76(12):2594-2598.
22. Li S, Yin CC, Medeiros LJ, Bueso-Ramos C, Lu G, Lin P. Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26.2;q22) is commonly a therapy-related disease associated with poor outcome. Am J Clin Pathol. 2012;138(1):146-152.
23. Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25(4): 415-427.
24. Gröschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangementcauses concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157(2): 369-381.
25. Métais JY, Dunbar CE. The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. Mol Ther. 2008;16(3):439-449.
26. Gröschel S, Sanders MA, Hoogenboezem R, et al. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. Blood. 2015;125(1): 133-139.
27. Theil KS, Cotta CV. The prognostic significance of an inv(3)(q21q26.2) in addition to a t(9;22)(q34; q11.2) in patients treated with tyrosine kinase inhibitors. Cancer Genet. 2014;207(5):171-176.
28. Paquette RL, Nicoll J, Chalukya M, et al. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genet. 2011;204(7):392-397.
29. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109(10): 4143-4150.
30. Wang W, Cortes JE, Lin P, et al. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors [published online ahead of print April 14, 2015]. Leukemia. doi: 10.1038/ leu.2015.96.
31. Radich JP. How I monitor residual disease in chronic myeloid leukemia. Blood. 2009;114(16): 3376-3381.
32. Sato T, Goyama S, Kataoka K, et al. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Oncogene. 2014;33(42):5028-5038.
33. Ogawa S, Kurokawa M, Tanaka T, et al. Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia. 1996;10(5):788-794.
34. Daghistani M, Marin D, Khorashad JS, et al. EVI-1 oncogene expression predicts survival in chronicphase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. Blood. 2010;116(26):6014-6017.
35. Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008; 111(8):4329-4337.
36. Arai S, Yoshimi A, Shimabe M, et al. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood. 2011;117(23):6304-6314.
37. Bindels EM, Havermans M, Lugthart S, et al. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 2012;119(24): 5838-5849.
38. Gröschel S, Lugthart S, Schlenk RF, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28(12):2101-2107.
39. Syed J, Pandian GN, Sato S, et al. Targeted suppression of EVI1 oncogene expression by sequence-specific pyrrole-imidazole polyamide. Chem Biol. 2014;21(10):1370-1380.
40. Wang W, Tang G, Cortes JE, et al. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015;8(1):32.